Home › Companies › IMVT

Immunovant

IMVT Rare disease Lead: Phase 3 6 Biotech Distilled articles ↓

Immunology Neurology Protein

Most recent annual filing: 2026-05-20

Pipeline (5 active programs)

imeroprubart

IMVT-1402

Protein Target: FcRn

Graves' Disease Phase 2 subcutaneous HanAll NCT06727604
Rheumatoid Arthritis Phase 2 subcutaneous HanAll NCT06754462
Myasthenia Gravis Phase 3 subcutaneous HanAll NCT07039916
Chronic Inflammatory Demyelinating Polyneuropathy Phase 2 subcutaneous HanAll NCT07032662
Sjögren's Disease Phase 2 subcutaneous HanAll NCT06979531

Discontinued (2)

imeroprubart — Cutaneous Lupus Erythematosus · missed primary endpoint; competitive landscape
batoclimab — Thyroid Eye Disease · Company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402

Biotech Distilled coverage (6)

2026-09-23 UPDATE: Immunovant (IMVT) - The First Placebo Test Comes Back Empty 🔒 Paid
2026-08-07 UPDATE: Immunovant (IMVT) - The Quarter Where the Burn Got Real
2026-05-20 UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check 🔒 Paid
2026-04-04 UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity 🔒 Paid
2026-02-07 UPDATE: Immunovant (IMVT) - Quarterly Update 🔒 Paid
2026-02-02 Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.